Healthcare Sales & Marketing Network News: Gabapentin Enacarbil

Searching News Database: Gabapentin Enacarbil

HSMN NewsFeed - 29 Jan 2014
XenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 23 Jul 2013
XenoPort Announces Inclusion of Horizant (Gabapentin Enacarbil) in Guidelines for Long-Term Treatment of Restless Legs Syndrome/Willis-Ekbom Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 18 Jun 2012
XenoPort Appoints Ernest Mario, Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 7 Jun 2012
GSK and XenoPort Receive FDA Approval for Horizant(R) for Postherpetic Neuralgia
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Jan 2012
Astellas and XenoPort Announce Approval of Regnite(R) Tablets for Restless Legs Syndrome in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 Mar 2010
XenoPort Restructures to Focus on Key Programs
Biopharmaceuticals

HSMN NewsFeed - 13 Apr 2009
XenoPort Announces Election of Co-Promotion Option for Solzira
Biopharmaceuticals

HSMN NewsFeed - 9 Jan 2009
GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 16 Sep 2008
GSK and XenoPort Announce Submission of New Drug Application Requesting FDA Approval of Solzira(TM) for Restless Legs Syndrome
Biopharmaceuticals

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.